Unfortunately, clinical trials for granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) as either prophylaxis or therapy for neonatal sepsis resulted in increased cell counts with no concurrent reduction in mortality (104). The gene discussed is CSF3; the disease is Neonatal sepsis.